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Background
Abacavir, a nucleoside reverse transcriptase inhibitor, is
used within drug combination therapy to treat the HIV-1
virus. It is a guanosine-analogue pro-drug, and once meta-
bolised to carbovir, it acts as a DNA chain terminator.
Exposure to abacavir is associated with a high frequency
of CD8+ T-cell-mediated hypersensitivity reactions in
individuals carrying the HLA risk allele B*57:01. To acti-
vate T-cells, abacavir interacts directly with endogenous
HLA-B*57:01, altering the repertoire of peptides displayed
on the cell surface. Docking studies show that the amino
cyclopropyl group at the 6-position of abacavir assists in
the arrangement and interaction of peptides with the
MHC binding pocket. We hypothesized that chemical
modification of abacavir at this position would provide a
new series of analogues with potent antiviral activity that
do not activate abacavir-specific CD8+ T-cells.
Methods
Fifteen analogues were synthesized and their anti-viral
activity measured. T cell responses to these analogues
was then measured using CD8+ clones generated from
HLA-B*57:01+ donors.
Results
Several analogues, including the key closely related com-
pounds, retained antiviral activity, but displayed highly
divergent T-cell responses. Three HLA-B*57:01 positive
blood donors were selected to generate abacavir-responsive
T-cell clones. IFN- release was visualized using ELISpot
to measure abacavir-specific T-cell responses and to
determine which analogues activated the T-cells. All of
the abacavir-responsive clones secreted IFN-, in a drug-
concentration-dependent fashion (EC50 [50% of maxi-
mal IFN- spot forming units] less than 20M for all
clones). A minimum of 5 clones were used to compare
abacavir specific responses against the analogues.
Abacavir and N-propyl abacavir were equally potent at
activating clones. In contrast, two very closely related
abacavir analogues were devoid of T-cell activity.
Conclusion
Our findings show that it is possible to block the T-cell
activity of abacavir while maintaining anti-viral activity by
simple chemical modification.
Authors’ details
1University of Liverpool, MRC Centre for Drug Safety Science, UK.
2GlaxoSmithKline, Drug Metabolism & Pharmacokinetics, UK.
Published: 18 July 2014
doi:10.1186/2045-7022-4-S3-P40
Cite this article as: Alhaidari et al.: Chemical modification of the 6’-amino
cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell
activation without loss of antiviral activity. Clinical and Translational Allergy
2014 4(Suppl 3):P40.
1University of Liverpool, MRC Centre for Drug Safety Science, UK
Full list of author information is available at the end of the article
Alhaidari et al. Clinical and Translational Allergy 2014, 4(Suppl 3):P40
http://www.ctajournal.com/content/4/S3/P40
© 2014 Alhaidari et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
